Centessa Pharmaceuticals Enters Material Definitive Agreement
Ticker: CNTA · Form: 8-K · Filed: Sep 13, 2024 · CIK: 1847903
| Field | Detail |
|---|---|
| Company | Centessa Pharmaceuticals PLC (CNTA) |
| Form Type | 8-K |
| Filed Date | Sep 13, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $14.75, $211.0 million, $242.7 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing
Related Tickers: CNTA
TL;DR
Centessa Pharma signed a big deal, filing an 8-K. Details TBD.
AI Summary
On September 12, 2024, Centessa Pharmaceuticals plc entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. Specific details of the agreement and financial information were not provided in this excerpt.
Why It Matters
This filing indicates a significant new agreement for Centessa Pharmaceuticals, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant implications, but the lack of specific details necessitates a medium risk assessment.
Key Players & Entities
- Centessa Pharmaceuticals plc (company) — Registrant
- September 12, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Centessa Pharmaceuticals?
The provided excerpt does not specify the nature of the material definitive agreement.
When was the material definitive agreement entered into?
The material definitive agreement was entered into on September 12, 2024.
What other items are reported in this 8-K filing?
The filing also reports on other events and includes financial statements and exhibits.
What is Centessa Pharmaceuticals' primary business sector?
Centessa Pharmaceuticals plc is in the Pharmaceutical Preparations sector, SIC code 2834.
Where is Centessa Pharmaceuticals incorporated?
Centessa Pharmaceuticals plc is incorporated in England and Wales.
Filing Stats: 1,232 words · 5 min read · ~4 pages · Grade level 12.4 · Accepted 2024-09-13 16:00:34
Key Financial Figures
- $14.75 — irm ADSs"), at a price to the public of $14.75 per ADS (the "Offering"). Pursuant to t
- $211.0 million — ffering expenses, will be approximately $211.0 million (or approximately $242.7 million if the
- $242.7 million — mately $211.0 million (or approximately $242.7 million if the underwriters exercise their over
Filing Documents
- d878816d8k.htm (8-K) — 35KB
- d878816dex11.htm (EX-1.1) — 206KB
- d878816dex51.htm (EX-5.1) — 53KB
- d878816dex991.htm (EX-99.1) — 7KB
- d878816dex992.htm (EX-99.2) — 7KB
- g878816g0913104141888.jpg (GRAPHIC) — 6KB
- g878816g0913104435217.jpg (GRAPHIC) — 6KB
- g878816g40i19.jpg (GRAPHIC) — 3KB
- 0001193125-24-218828.txt ( ) — 570KB
- cnta-20240912.xsd (EX-101.SCH) — 3KB
- cnta-20240912_def.xml (EX-101.DEF) — 14KB
- cnta-20240912_lab.xml (EX-101.LAB) — 24KB
- cnta-20240912_pre.xml (EX-101.PRE) — 15KB
- d878816d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. 1.1 Underwriting Agreement dated September 12, 2024 5.1 Opinion of Goodwin Procter (UK) LLP 23.1 Consent of Goodwin Procter (UK) LLP (contained in Exhibit 5.1) 99.1 Launch Press Release dated September 11, 2024 99.2 Pricing Press Release dated September 12, 2024 104 Cover Page Interactive Data (embedded within the Inline XBRL document)
Forward Looking Statements
Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements. These statements may be identified by words such as "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "potential," "continue," "ongoing," "aim," "seek," and variations of these words or similar expressions that are intended to identify forward-looking statements. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995 Any such statements in this Current Report on Form 8-K that are not statements of historical fact may be deemed to be forward-looking statements, including statements related to the Company's ability to complete this Offering and its use of proceeds. Any forward-looking statements in this Current Report on Form 8-K are based on the Company's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and its other reports, which are on file with the U.S. Securities and Exchange Commission. The Company's explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 13, 2024 CENTESSA PHARMACEUTICALS PLC By: /s/ Saurabh Saha Name: Saurabh Saha, M.D., Ph.D. Title: Chief Executive Officer